1. You are asked to deliver an in-service to your pharmacy colleagues regarding the role of combining BRAF and MEK inhibitors for the treatment of metastatic melanoma. Which of the following points should be included?

2. DK is a 31-year-old male initially diagnosed with melanoma of the left lower abdomen. A CT scan of the chest, abdomen, and pelvis revealed metastatic spread to right hilar and axillary lymph nodes, lung, and bones. He is experiencing significant shortness of breath and pain from his disease. Next generation sequencing reveals a BRAF V600K mutation. Which of the following first-line treatment options is most appropriate for DK?

3. CV is a 45-year-old female with newly diagnosed stage IIIC melanoma with no satellite or in transit lesions. Next generation sequencing confirmed the presence of a BRAF V600E mutation. Following complete wide excision, which of the following adjuvant treatments is most appropriate?

4. HG is a 46-year-old female with a right auricular melanoma with metastases to the lung and soft tissue. Pathology is positive for a BRAF V600E mutation. After the first cycle of dabrafenib + trametinib, HG reports that she had several days of fever greater than 102°F. With her fever episodes, she also experienced chills, rigors, and night sweats. Her temperature in the office today is 101.7°F, and she is normotensive. Which of the following is the most appropriate first-line management of HG's pyrexia?

5. SJ is a 67-year-old-male with melanoma metastatic to the lungs and liver. Pathology is positive for a BRAF V600E mutation. She is symptomatic with cough and shortness of breath and will commence encorafenib + binimetinib. Which of the following assessments should be obtained prior to and throughout BRAF + MEK inhibitor therapies?

Evaluation Questions

6. How confident are in your treatment choice for SJ in question #5 above?

« Return to Activity